Literature DB >> 32241816

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.

Junya Ichikawa1, Tatsuya Yoshida2, Ariel Isser3, Andressa S Laino2, Melinda Vassallo2, David Woods2, Sojung Kim4, Mathias Oelke4, Kristi Jones4, Jonathan P Schneck3, Jeffrey S Weber1.   

Abstract

PURPOSE: Generation of antigen-specific T cells from patients with cancer employs large numbers of peripheral blood cells and/or tumor-infiltrating cells to generate antigen-presenting and effector cells commonly requiring multiple rounds of restimulation ex vivo. We used a novel paramagnetic, nanoparticle-based artificial antigen-presenting cell (nano-aAPC) that combines anti-CD28 costimulatory and human MHC class I molecules that are loaded with antigenic peptides to rapidly expand tumor antigen-specific T cells from patients with melanoma. EXPERIMENTAL
DESIGN: Nano-aAPC-expressing HLA-A*0201 molecules and costimulatory anti-CD28 antibody and HLA-A*0201 molecules loaded with MART-1 or gp100 class I-restricted peptides were used to stimulate CD8 T cells purified from the peripheral blood of treatment-naïve or PD-1 antibody-treated patients with stage IV melanoma. Expanded cells were restimulated with fresh peptide-pulsed nano-aAPC at day 7. Phenotype analysis and functional assays including cytokine release, cytolysis, and measurement of avidity were conducted.
RESULTS: MART-1-specific CD8 T cells rapidly expanded up to 1,000-fold by day 14 after exposure to peptide-pulsed nano-aAPC. Expanded T cells had a predominantly stem cell memory CD45RA+/CD62L+/CD95+ phenotype; expressed ICOS, PD-1, Tim3, and LAG3; and lacked CD28. Cells from patients with melanoma were polyfunctional; highly avid; expressed IL2, IFNγ, and TNFα; and exhibited cytolytic activity against tumor cell lines. They expanded 2- to 3-fold after exposure to PD-1 antibody in vivo, and expressed a highly diverse T-cell receptor V beta repertoire.
CONCLUSIONS: Peptide-pulsed nano-aAPC rapidly expanded polyfunctional antigen-specific CD8 T cells with high avidity, potent lytic function, and a stem cell memory phenotype from patients with melanoma. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32241816      PMCID: PMC7334099          DOI: 10.1158/1078-0432.CCR-19-3487

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  60 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

2.  Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.

Authors:  Di-Hwei Hsu; Pedro Paz; Gilbert Villaflor; Alberto Rivas; Anita Mehta-Damani; Eric Angevin; Laurence Zitvogel; Jean-Bernard Le Pecq
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

3.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

4.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

Authors:  Alena Gros; Maria R Parkhurst; Eric Tran; Anna Pasetto; Paul F Robbins; Sadia Ilyas; Todd D Prickett; Jared J Gartner; Jessica S Crystal; Ilana M Roberts; Kasia Trebska-McGowan; John R Wunderlich; James C Yang; Steven A Rosenberg
Journal:  Nat Med       Date:  2016-02-22       Impact factor: 53.440

5.  Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Authors:  Yun Lin; Humilidad F Gallardo; Geoffrey Y Ku; Hao Li; Gregor Manukian; Teresa S Rasalan; Yinyan Xu; Stephanie L Terzulli; Lloyd J Old; James P Allison; Alan N Houghton; Jedd D Wolchok; Jianda Yuan
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

6.  Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors.

Authors:  Chuan Jin; Di Yu; Victoria Hillerdal; AnnaCarin Wallgren; Alex Karlsson-Parra; Magnus Essand
Journal:  Mol Ther Methods Clin Dev       Date:  2014-03-05       Impact factor: 6.698

7.  Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.

Authors:  Aude G Chapuis; Sylvia M Lee; John A Thompson; Ilana M Roberts; Kim A Margolin; Shailender Bhatia; Heather L Sloan; Ivy Lai; Felecia Wagener; Kendall Shibuya; Jianhong Cao; Jedd D Wolchok; Philip D Greenberg; Cassian Yee
Journal:  J Exp Med       Date:  2016-05-30       Impact factor: 14.307

8.  Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery.

Authors:  Jorieke Weiden; Dion Voerman; Yusuf Dölen; Rajat K Das; Anne van Duffelen; Roel Hammink; Loek J Eggermont; Alan E Rowan; Jurjen Tel; Carl G Figdor
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561

9.  Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation.

Authors:  Randall A Meyer; Joel C Sunshine; Karlo Perica; Alyssa K Kosmides; Kent Aje; Jonathan P Schneck; Jordan J Green
Journal:  Small       Date:  2015-01-12       Impact factor: 13.281

10.  Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells.

Authors:  Alexander S Cheung; David K Y Zhang; Sandeep T Koshy; David J Mooney
Journal:  Nat Biotechnol       Date:  2018-01-15       Impact factor: 54.908

View more
  8 in total

Review 1.  AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties.

Authors:  Lauren Suarez; Ruipeng Wang; Scott Carmer; Daniel Bednarik; Han Myint; Kristi Jones; Mathias Oelke
Journal:  Transfus Med Hemother       Date:  2020-11-16       Impact factor: 3.747

2.  Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies.

Authors:  Britta Eiz-Vesper; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-10       Impact factor: 3.747

Review 3.  Nanoparticles for generating antigen-specific T cells for immunotherapy.

Authors:  Savannah E Est-Witte; Natalie K Livingston; Mary O Omotoso; Jordan J Green; Jonathan P Schneck
Journal:  Semin Immunol       Date:  2021-12-23       Impact factor: 11.130

Review 4.  Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.

Authors:  Leila Pourtalebi Jahromi; Mohammad-Ali Shahbazi; Aziz Maleki; Amir Azadi; Hélder A Santos
Journal:  Adv Sci (Weinh)       Date:  2021-03-01       Impact factor: 16.806

Review 5.  Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.

Authors:  Ariel Isser; Natalie K Livingston; Jonathan P Schneck
Journal:  Biomaterials       Date:  2020-12-05       Impact factor: 15.304

Review 6.  Emerging vaccine nanotechnology: From defense against infection to sniping cancer.

Authors:  Chan Feng; Yongjiang Li; Bijan Emiliano Ferdows; Dylan Neal Patel; Jiang Ouyang; Zhongmin Tang; Na Kong; Enguo Chen; Wei Tao
Journal:  Acta Pharm Sin B       Date:  2022-01-04       Impact factor: 14.903

Review 7.  Nanotechnology-enhanced immunotherapy for metastatic cancer.

Authors:  Peisen Zhang; Junli Meng; Yingying Li; Chen Yang; Yi Hou; Wen Tang; Kevin J McHugh; Lihong Jing
Journal:  Innovation (Camb)       Date:  2021-10-14

8.  Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy.

Authors:  Ariel Isser; Aliyah B Silver; Hawley C Pruitt; Michal Mass; Emma H Elias; Gohta Aihara; Si-Sim Kang; Niklas Bachmann; Ying-Yu Chen; Elissa K Leonard; Joan G Bieler; Worarat Chaisawangwong; Joseph Choy; Sydney R Shannon; Sharon Gerecht; Jeffrey S Weber; Jamie B Spangler; Jonathan P Schneck
Journal:  Nat Commun       Date:  2022-10-14       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.